AKT1 and breast carcinoma: The levels of p-Akt were also decreased in MCF-7s breast cancer cells, confirming the inhibition of PI3K/AKT pathway was associated with the inhibition of Wnt/β-catenin pathway in breast cancer under pristimerin treatment (50).